Taurodeoxycholic-acid-DataSheet-生命科学试剂-MCE

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemETaurodeoxycholicacidCat.No.:HY-B1899CASNo.:516-50-7分⼦式:C₂₆H₄₅NO₆S分⼦量:499.7作⽤靶点:EndogenousMetabolite;Apoptosis作⽤通路:MetabolicEnzyme/Protease;Apoptosis储存⽅式:-20°C,protectfromlight*Insolvent:-80°C,6months;-20°C,1month(protectfrom

light)溶解性数据体外实验DMSO:100mg/mL(200.12mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制备储备液1mM2.0012mL10.0060mL20.0120mL5mM0.4002mL2.0012mL4.0024mL10mM0.2001mL1.0006mL2.0012mL请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存⽅式和期限：-80°C,6months;-20°C,1month(protectfromlight)。-80°C储存时，请在6个⽉内使⽤，-20°C储存时，请在1个⽉内使⽤。体内实验请根据您的实验动物和给药⽅式选择适当的溶解⽅案。以下溶解⽅案都请先按照InVitro⽅式配制澄的储备液，再依次添加助溶剂：(为保证实验结果的可靠性，澄的储备液可以根据储存条件，适当保存；体内实验的⼯作液，建议您现⽤现配，当天使⽤；以下溶剂前显⽰的百分⽐指该溶剂在您配制终溶液中的体积占⽐；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的⽅式助溶)1.请依序添加每种溶剂：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.5mg/mL(5.00mM);Clearsolution2.请依序添加每种溶剂：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(5.00mM);Clearsolution1/2MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemE3.请依序添加每种溶剂：10%DMSO>>90%cornoilSolubility:≥2.5mg/mL(5.00mM);ClearsolutionBIOLOGICALACTIVITY⽣物活性Taurodeoxycholicacid⼀种胆汁酸，可稳定线粒体膜，减少⾃由形成。Taurodeoxycholicacid通过阻断钙介导的凋亡通路以及Caspase-12激活来抑制凋亡(apoptosis)。Taurodeoxycholicacid对3-硝丙酸诱导或稳定遗传的亨廷顿舞蹈病(HD)⼩⿏模型具有神经保护作⽤。IC50&TargetMicrobialMetabolite体外研究Taurodeoxycholicacid(50μM,100μM;4h)increasesoligonucleosomalDNAcleavageandapoptoticnucleiinprimaryhumanhepatocytes[1].Taurodeoxycholicacid(400μM;18-24h)increasesDNAfragmentationandPARPcleavageinhumanliver-derivedcelllineHuh7cells,thusinducesapoptosis[2].体内研究Taurodeoxycholicacid(50mg/kg;i.p.;oncedaliyfor34d)preventsneuropathologyandassociatedbehavioraldeficitsinthe3-nitropropionicacidratmodelofHuntington'sdisease(HD)[3].Taurodeoxycholicacid(500mg/kg;s.c.;onceevery3dfor7weeks)leadstoasignificantreductioninstriatalneuropathologyoftheR6/2transgenicHDmouse[4].AnimalModel:Huntington'sdiseasemodelinmouse[3]Dosage:50mg/kgAdministration:Intraperitonealinjection;oncedaliyfor34d,injected3-NPat6hrafterTaurodeoxycholicacidtreatmentResult:Reducedstriatalatrophy,decreasedstriatalapoptosis,aswellasfewerandsmallersizeubiquitinatedneuronalintranuclearhuntingtininclusions.Significantlyimprovedlocomotorandsensorimotordeficits.REFERENCES[1].BenzC,etal.Effectoftauroursodeoxycholicacidonbileacid-inducedapoptosisinprimaryhumanhepatocytes.EurJClinInvest.2000Mar;30(3):203-9.[2].XieQ,etal.Effectoftauroursodeoxycholicacidonendoplasmicreticulumstress-inducedcaspase-12activation.Hepatology.2002Sep;36(3):592-601.[3].KeeneCD,etal.Abileacidprotectsagainstmotorandcognitivedeficitsandreducesstriataldegenerationinthe3-nitropropionicacidmodelofHuntington'sdisease.ExpNeurol.2001Oct;171(2):351-60.[4].KeeneCD,etal.Tauroursodeoxycholicacid,abileacid,isneuroprotectiveinatransgenicanimalmodelofHuntington'sdisease.ProcNatlAcadSciUSA.2002Aug6;99(16):10671-6.McePdfHeight2/2MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemECaution:Producthasnotbeenful